REGN4461 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 265 | Lipodystrophy | 3 |
265. Lipodystrophy
Clinical trials : 112 / Drugs : 155 - (DrugBank : 55) / Drug target genes : 25 - Drug target pathways : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05088460 (ClinicalTrials.gov) | February 28, 2022 | 12/10/2021 | A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) | A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients With Familial Partial Lipodystrophy | Familial Partial Lipodystrophy;Metabolic Abnormalities | Drug: REGN4461;Drug: Matching Placebo | Regeneron Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 2 | United States;France;Spain;Turkey |
| 2 | NCT04710056 (ClinicalTrials.gov) | June 2021 | 13/1/2021 | Expanded Access to REGN4461 for Patients With 1) Generalized Lipodystrophy, 2) Partial Lipodystrophy or 3) Monogenic Obesity Due to LEP or LEPR Loss of Function | Generalized Lipodystrophy;Partial Lipodystrophy;Monogenic Obesity Due to LEP or LEPR Loss of Function | Drug: REGN4461 | Regeneron Pharmaceuticals | NULL | Available | NULL | ||||||
| 3 | NCT04159415 (ClinicalTrials.gov) | January 7, 2020 | 7/11/2019 | Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy | A Randomized, Double-Blind, Placebo-Controlled Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy | Generalized Lipodystrophy | Drug: Placebo;Drug: Low-Dose REGN4461;Drug: High-dose REGN4461 | Regeneron Pharmaceuticals | NULL | Active, not recruiting | 12 Years | N/A | All | 16 | Phase 2 | United States;Peru;Russian Federation;Turkey |